Head and Neck Cancer
Conditions
Keywords
stage IV salivary gland cancer, recurrent salivary gland cancer, salivary gland adenoid cystic carcinoma, stage IV adenoid cystic carcinoma of the oral cavity, recurrent adenoid cystic carcinoma of the oral cavity
Brief summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of gemcitabine in treating patients who have recurrent or metastatic adenoid cystic cancer of the head and neck.
Detailed description
OBJECTIVES: * Assess the therapeutic activity of gemcitabine, in terms of objective response and duration of response, in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck. * Determine the acute toxicity of this drug in these patients. OUTLINE: This is a multicenter study. Patients receive gemcitabine IV over 30-60 minutes on days 1 and 8. Treatment repeats every 21 days for a maximum of 12 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 12 weeks until disease progression and then every 6 months thereafter. PROJECTED ACCRUAL: A total of 16-29 patients will be accrued for this study.
Interventions
DRUGgemcitabine hydrochloride
Sponsors
European Organisation for Research and Treatment of Cancer - EORTC
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed metastatic or recurrent adenoid cystic carcinoma of the head and neck for which no curative options exist * Symptomatic and/or progressive disease * At least 1 unidimensionally measurable lesion * At least 20 mm by conventional techniques OR * At least 10 mm by spiral CT scan * No bone metastases as only lesion * Prior radiotherapy to only target lesion allowed if it has progressed or reappeared after radiotherapy * No CNS metastases PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * WHO 0-2 Life expectancy: * Not specified Hematopoietic: * WBC at least 3,500/mm\^3 * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 * Hemoglobin at least 10 g/dL Hepatic: * Bilirubin no greater than 1.25 times upper limit of normal (ULN) (2.5 times ULN if liver metastases present) * AST or ALT less than 3 times ULN (5 times ULN if liver metastases present) Renal: * Creatinine no greater than 1.7 mg/dL Other: * No uncontrolled infection * No concurrent serious systemic disorders that would preclude study * No other prior or concurrent malignancy except: * Adequately treated carcinoma in situ of the cervix * Basal cell or squamous cell skin cancer * Any malignancy that occurred more than 5 years ago with no symptoms or signs of recurrence (except malignant melanoma, hypernephroma, or breast carcinoma) * No psychological, familial, sociological, or geographical condition that would preclude study compliance * Not pregnant or nursing * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * No concurrent immunotherapy Chemotherapy: * No prior chemotherapy * No other concurrent chemotherapy Endocrine therapy: * No concurrent anti-estrogen therapy * Concurrent steroid replacement or steroids as an antiemetic allowed Radiotherapy: * See Disease Characteristics * At least 3 months since prior radiotherapy except for palliative radiotherapy to bone lesions * No concurrent radiotherapy Surgery: * Not specified Other: * At least 1 month since prior investigational agents * No other concurrent experimental medications
Countries
Belgium, Italy, Netherlands
Outcome results
None listed